熱點掃描 | 藥物開發宣告失敗,開拓藥業遭腰斬
uSMART盈立智投12月28日消息,截止發稿,港股三大指數漲跌互現,恆生指數微漲0.12% 報23251.23點,成交額423.48億;恆生科技指數跌0.76%,報5576.72點,成交額96.43億;紅籌指數漲0.54%報3964.92點,成交額15.61億。
開拓藥業宣佈第三期臨牀試驗的中期分析未達到統計學的顯著性,即表明藥物開發失敗。早盤該股閃崩超80%,當前股價爲14.9港元。
百心安漲超13%,重回發行價上方,當前價格爲23.150港元。
本年碳酸鋰價格暴漲超300%,單12月以來漲幅就超30%,當前贛鋒鋰業漲3.26%,股價收120.3港元。
騰訊控股跌2.35%,美團跌3.01%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.